Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our market websites.
-
ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV
ViiV Healthcare today announced the submission of a regulatory application in the US for its investigational single-tablet regimen (STR) combining dolutegravir, abacavir and lam...
Read more -
Regulatory update – GSK and Genmab announce submission to US regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
GSK and Genmab A/S announced today the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for the use of Arzerra® (ofatumuma...
Read more -
Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children
Results from a large-scale Phase III trial, presented today in Durban, show that the most clinically advanced malaria vaccine candidate, RTS,S, continued to protect young childr...
Read more -
Regulatory update – GSK and Genmab announce European submission to regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)
GSK and Genmab A/S announced today the submission of a variation to the Marketing Authorisation to the European Medicines Agency (EMA) for the use of Arzerra (ofatumumab) in com...
Read more -
GlaxoSmithKline reaches agreement with Aspen to divest thrombosis brands and related manufacturing site for £0.7 billion
Divestment supports strategic focus and delivery of pipeline.
Read more -
GSK and Barclays form partnership to increase access to healthcare and promote economic development in Zambia
GSK and Barclays have formed a new partnership which aims to increase access to affordable healthcare and medicines for people in Zambia, while helping to create improved econom...
Read more -
GSK receives marketing authorisation from the European Commission for additional Revolade™
GSK announced today that the European Commission has granted an additional indication for Revolade™ (eltrombopag) as a treatment for low platelet counts (thrombocytopenia) in ad...
Read more -
RELVAR™ ELLIPTA™ gains approval in Japan for the treatment of asthma
GSK and Theravance, Inc. today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment of bronchial asthma.
Read more -
GSK and Prosensa announce primary endpoint not met in Phase III study of drisapersen in patients with Duchenne Muscular Dystrophy
GSK and Prosensa today announced that GSK's Phase III clinical study of drisapersen, an investigational antisense oligonucleotide, for the treatment of Duchenne Muscular Dystrop...
Read more -
GSK signs a multi-year agreement with BARDA to supply the US government with anthrax treatment
GlaxoSmithKline (GSK) plc today announced a new four year contract with the Biomedical Advanced Research and Development Authority (BARDA).
Read more -
RELVAR™ ELLIPTA™ receives positive opinion from the CHMP in Europe for the treatment of asthma and COPD
GSK and Theravance, Inc. today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommend...
Read more -
GSK receives Priority Review from FDA for dabrafenib/trametinib combination in metastatic melanoma
GSK today announced that the US Food and Drug Administration (FDA) has granted Priority Review designation to its supplemental New Drug Applications (sNDAs) for combined use of ...
Read more -
GSK statement in response to patent ruling reversal on Lovaza
GSK confirmed today that the Court of Appeals for the Federal Circuit has ruled against Pronova Biopharma Norge AS in its patent litigation regarding Lovaza® (omega-3-acid ethyl...
Read more -
FDA grants GSK and Genmab’s Arzerra® (ofatumumab) Breakthrough Therapy designation for previously untreated chronic lymphocytic leukaemia
GSK and Genmab A/S announced today that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Arzerra® (ofatumumab) in combination with chlo...
Read more -
ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1
ViiV Healthcare today announced initial results from the Phase IIIb/IV FLAMINGO (ING114915) study.
Read more -
FDA Advisory Committee recommends approval in US of umeclidinium/vilanterol for the treatment of COPD
GSK and Theravance, Inc. today announced that the Pulmonary-Allergy Drugs Advisory Committee (PADAC) to the US Food and Drug Administration (FDA) voted 11 yes to 2 no that the e...
Read more -
GSK reaches agreement to divest Lucozade and Ribena for £1.35 billion
GSK today announced it has reached agreement to sell its nutritional drinks brands Lucozade and Ribena to Suntory Beverage & Food Ltd.
Read more -
The investigational MAGE-A3 antigen-specific cancer immunotherapeutic does not meet first co-primary endpoint in Phase III melanoma clinical trial
In line with the Independent Data Monitoring Committee's (IDMC) unanimous recommendation, GSK will continue the DERMA trial until the second co-primary endpoint is assessed.
Read more -
GSK receives marketing authorisation from the European Commission for Tafinlar™
GSK announced today that the European Commission has granted marketing authorisation for Tafinlar™ (dabrafenib).
Read more -
GSK announces phase III study of vercirnon in patients with moderate-to-severe Crohn’s disease did not meet its primary endpoint
GSK announced that the first of four Phase III studies, the SHIELD-1 study, investigating vercirnon - an investigational CCR9 antagonist - in adult patients with moderately-to-s...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose to improve the quality of human life.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines & consumer healthcare from inside and outside our labs. Go #BehindTheScience to see for yourself
